Latest News

The Australian Cardiovascular Alliance (ACvA) and Hypertension Australia (formerly the High Blood Pressure Research Council of Australia) have joined forces to establish a National Hypertension Taskforce with the ambitious goal to double Australia’s rates of controlled blood pressure from 32% to 70% by 2030. “If all Australians currently living with high blood pressure were properly …

A global study of over 28,000 people has provided the strongest evidence to date that lowering blood pressure in later life can cut the risk of dementia. Dr Ruth Peters, Associate Professor at UNSW Sydney and Program Lead for Dementia in The George Institute’s Global Brain Health Initiative, said that in the absence of significant …

Remote cellular-enabled blood pressure monitoring provides novel and secure way of collecting real world data (RWD) in decentralised global phase III pivotal study. Unique remote device monitoring (RDM) capabilities of Medisanté’s medical IoT platform (M+ Hub) enhance George Medicines’ clinical trial management system. Seamless decentralised data collection of blood pressure measurements over a secure private cellular …

Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage development with global Phase III trials underway Single-pill triple combination outperformed standard treatments without additional adverse effects in earlier clinical research VERONICA-Nigeria trial aims for more than 80% blood pressure control while improving cost-effectiveness in treating hypertension, providing a potential valuable tool to address the growing …

GMRx4 is the second candidate to be prioritised in Company’s pipeline of proprietary fixed-dose combination therapies targeting non-communicable diseases George Medicines receives $1.5 million investment from Australia’s national biotechnology incubator CUREator London, UK, 20 July 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes …

A new multi-faceted partnership supported by George Clinical will move to the forefront of the cancer treatment revolution. The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub building links from research through to the clinic; creating jobs and changing lives. Over the past decade, immunotherapy and other …

LONDON | 27 FEBRUARY   Findings from preliminary tests of a new dialysis system have confirmed its ability to make sterile, medical grade water to provide an affordable, accessible home-based treatment option for patients with kidney failure. This means that the Ellen Medical Devices Point-of-Care dialysis system can create peritoneal dialysis fluid (a mix of sterile …

500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to substantially increase efficacy and improve adherence to treatment, while minimising side effects London, UK, January 17 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, …

Sydney-based start-up Ellen Medical Devices will receive $427,500 in government funding that will be matched by the company, making a total investment of $1.04 million to develop its award-winning Ellen Medical Dialysis System. The investment is part of the Advanced Manufacturing Growth Centre’s (AMGC) $30 million Commercialisation Fund supporting innovative Australian businesses to grow their manufacturing …

London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Dr Charmaine Gittleson to the Board as Independent Non-Executive Director. Dr Gittleson has extensive international experience as a pharmaceutical physician and enterprise leader. Prior …

Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research. Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes. London, UK, 1 July 2021 …

Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for non-communicable diseases. US FDA grants IND authorization to commence Phase III trials with triple combination candidate for the treatment of hypertension. Chief Business Officer, Karl Roberts, appointed to new role of Chief Operating Officer. London, UK, 3 June 2021 – …

SYDNEY, NOV 20 – A new Australian product designed to make kidney dialysis more broadly available at low cost has won first prize in a global health innovations competition. The Affordable Dialysis System, developed by Sydney-based Ellen Medical, beat more than 500 entries from 22 countries to score top prize in the World Innovation Summit for …

On March 10, The George Institute for Global Health announced a $53 million investment to support the commercialisation of the Institute’s world-leading research. The funding from three Australian investors will help address some of the biggest health challenges of our time – heart disease, high blood pressure and diabetes. Together with key partners and collaborators, policy makers …

SYDNEY, MARCH 10 – The George Institute for Global Health today announced that $53 million from three Australian investors will now support the commercialisation of its world-leading research to address some of the biggest health challenges of our time. The investments are set to fast-track the growth of George Health Enterprises, the Institute’s commercial arm, and George …